SCYX Stock Recent News

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to other assets derived from Brexafemme.

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an antifungal for the treatment of vulvovaginal candidiasis and the reduction of the incidence of recurrent VVC.

SCYNEXIS, Inc. (NASDAQ:SCYX ) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr. Marco Taglietti - President & CEO Dr. David Angulo - Chief Medical Officer Ivor Macleod - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Michael Higgins - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good morning, and welcome to the SCYNEXIS Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022.

Scynexis launched a product for VVC where there is no significant commercial demand. An additional indication in preventing VVC is not likely to significantly increase sales.

JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexafungerp for the treatment of patients intolerant of, or with fungal disease refractory to, standard antifungal therapy will be presented during IDWeek 2022 being held in Washington, D.C October 19-23, 2022.

JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.

SCYNEXIS, Inc. (NASDAQ:SCYX ) Q2 2022 Results Conference Call August 15, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine Coyne - Chief Commercial Officer Dr. David Angulo - Chief Medical Officer Larry Hoffman - Interim CFO Conference Call Participants Carvey Leung - Cantor Fitzgerald Farhana Sakloth - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Kumar Raja - Brookline Capital Markets Steve Brozak - WBB Securities Operator Ladies and gentlemen, good morning, and welcome to SCYNEXIS, Inc. Second Quarter 2022 Earnings Conference Call.

Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?